We are testing whether zongertinib can help people with advanced solid tumors that have HER2 mutations or overexpression. The study will evaluate its effectiveness, safety, and how patients respond to the treatment.
Health conditions and diseases that the clinical trial is designed to study and treat.
HER2-mutated or overexpressed/amplified solid tumors are a type of cancer where the HER2 gene is altered or overproduced, leading to aggressive tumor growth. This condition is often associated with breast cancer but can occur in other solid tumors as well.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
